California Public Employees Retirement System
IMDX

California Public Employees Retirement System’s Insight Molecular Diagnostics IMDX Stock Holding History

California Public Employees Retirement System’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-509
Closed -$14K – 3578
2020
Q3 		$14K Hold
509
– – ﹤0.01% 3533
2020
Q2 		$19K Buy
+509
New +$26.3K ﹤0.01% 3480

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

California Public Employees Retirement System's IMDX Position: Q4 2020 in Review

California Public Employees Retirement System sold out of Insight Molecular Diagnostics (IMDX) in Q4 2020, closing a stake of 509 shares — an estimated $14K sold.

California Public Employees Retirement System first reported a position in IMDX in Q2 2020 and held it in 2 quarters. The position peaked at $19K in Q2 2020. 60 funds tracked by Wall St. Rank hold IMDX as of Q4 2020.

  • California Public Employees Retirement System reported no remaining Insight Molecular Diagnostics position as of Q4 2020 after selling out during the quarter.
  • California Public Employees Retirement System sold 509 Insight Molecular Diagnostics shares in Q4 2020, an estimated $14K.
  • California Public Employees Retirement System first reported a position in Insight Molecular Diagnostics in Q2 2020 and held it in 2 quarters.
  • California Public Employees Retirement System's Insight Molecular Diagnostics position peaked at $19K in Q2 2020.
  • 60 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2020.

Based on California Public Employees Retirement System's 13F filing for Q4 2020, filed 2 Feb 2021.